Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29878860 | 0.84 | KDM4E (0.42) | DAGLASMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL19895802 | 0.79 | PSMD14 (0.42) | — | |
| SCHEMBL6109454 | 0.79 | DAGLA (0.41) | DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A | |
| SCHEMBL5546211 | 0.76 | ELANE (0.44) | DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A | |
| SCHEMBL1121652 | 0.76 | — | — | |
| SCHEMBL5485869 | 0.76 | PSMB8 (0.35) | SMN1; SMN2RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL3656157 | 0.76 | DAGLA (0.40) | DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A | |
| SCHEMBL9390262 | 0.76 | ELANE (0.39) | SMN1; SMN2RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL5546209 | 0.76 | DAGLA (0.40) | DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A | |
| SCHEMBL13279633 | 0.76 | SMN1; SMN2 (0.43) | DAGLASMN1; SMN2PIK3CDPIK3CBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0572893-A1 | Fluor-benzoxazolyloxyacetamides | BAYER AG (DE) | 1993-12-08 | — | — | EP | claimed |
| CN-115124485-B | Sulfoxide-containing benzoxazole derivative, and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-12-15 | — | — | CN | disclosed |
| CN-115124485-A | Benzoxazole derivatives containing sulfoxide as well as preparation method and application thereof | 中国医学科学院药物研究所 | 2022-09-30 | — | — | CN | disclosed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| CN-105431427-B | Novel PDE 4 inhibitor | 明治制果药业株式会社 | 2017-12-08 | — | — | CN | disclosed |
| CN-105431427-A | Novel PDE4 inhibitor | MEIJI SEIKA PHARMA CO LTD | 2016-03-23 | — | — | CN | disclosed |
| US-8753895-B2 | Surface modified metal nano-particle and use thereof | Postech Academy-Industries Foundation (KR) | 2014-06-17 | — | — | US | disclosed |
| US-20130252274-A1 | Surface Modified Metal Nano-Particle and Use Thereof | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2013-09-26 | — | — | US | disclosed |
| US-20120168681-A1 | Surface Modified Metal Nano-Particle and Use Thereof | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2012-07-05 | — | — | US | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2234999-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-5347008-A | Thio(cyclo) alkanepolycarboxylic acids containing heterocyclic substituents | CIBA-GEIGY CORPORATION (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0572893-A1 | Fluor-benzoxazolyloxyacetamides | BAYER AG (DE) | 1993-12-08 | — | — | EP | disclosed |
| EP-0129506-A2 | Heterocyclically substituted thio(cyclo)alkane polycarboxylic acids | CIBA-GEIGY AG (CH) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | DAGLA 2737/4885SMN1; SMN2 2577/4885PIK3CD 3339/4885 |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | DAGLA 3706/4885SMN1; SMN2 4315/4885PIK3CD 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.